AcelRx Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update


August 1, 2017 (STL.News) In the second quarter of 2017, AcelRx presented efficacy and integrated safety results from the DSUVIA™ (sufentanil sublingual tablet, 30 mcg) clinical program during the Annual Regional Anesthesiology and Acute Pain Medicine Meeting. DSUVIA is AcelRx s lead investigational candidate for the treatment of patients with moderate-to-severe acute pain in a medically [ ] The post AcelRx Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update appeared first on STL News.
http://bit.ly/2u08ZJh

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Create a website or blog at WordPress.com

Up ↑

%d bloggers like this: